Trasylol
On December 2, 2008, Siskinds filed a class proceeding against Bayer with respect to their drug Trasylol ("aprotinin"), which was injected into individuals undergoing heart surgery to help reduce bleeding and the need for blood transfusions. Bayer suspended marketing of Trasylol following results from a clinical trial that suggested an increased risk of death. Use of Trasylol during surgery has been associated with an increased risk of developing cardiovascular or cerebrovascular adverse events, renal dysfunction, or death. The Statement of Claim alleges that Bayer failed to adequately warn patients and physicians of the increased risk of serious adverse injury associated with use of Trasylol as compared to safer alternatives.
• Press Release (English)
• Press Release (French)
A Certification hearing has been scheduled for October 30 – November 1, 2012.
For further information concerning this action, please contact Megan Johnston at 519-672-2251 ext. 2409 or e-mail Megan by clicking on the Contact Us link below.
Back to Siskinds Actions

The documents available on this page require the latest version of Adobe Acrobat Reader for viewing.
Click Here to download.